Model Drugs Announces Oncology Programs Launch With Multiple AI-Detected Compounds Showing Drug-Like Activity For Two High Values, Hard-to-Drugs, Oncogenes and Oncogenes

  • AXL and BRD4 are oncogenic and epigenetic targets of high biological relevance, respectively, implicated in many indications including both hematological and solid malignancies, but have historically been a major drug challenge.
  • The Galileo™ platform from Model Medicine has detected several new chemotypes of AXL and BRD4 that show nanomolar activity or low micromolar activity in in the laboratory Validation studies.
  • Guided by the indications’ target product profiles, the company plans to rapidly move the promising compounds to preclinical proof of concept.

La Jolla, California.And the 4 October 2022 /PRNewswire/- Typical MedicinesThe pharmaceutical company that is transforming the drug discovery and development industry using artificial intelligence (AI), today announced the launch of its oncology programs. The programs focus on the discovery and development of therapeutics against two tumorigenic and epigenetic targets – AXL and BRD4 – with applications in numerous indications, including hematological and solid malignancies. The company reported the discovery of several chemical patterns that display nano- or small-scale activity against AXL and BRD4, which represent completely new drugs for these targets. The announcement follows the company’s announcement for the second quarter of 2022 that its AI-discovered lead compound MDL-001, developed in collaboration with world-renowned researchers at Scripps Research and the Icahn School of Medicine at Mount Sinai, demonstrated a preclinical, best-in-class proof-of-concept as a spectrum. Potential therapeutic for infectious diseases.

Model Medicines announces the launch of its own oncology programs with multiple AI-detected compounds for two purposes.

The AXL signaling pathway has been demonstrated to lead to cancer cell survival, proliferation, migration and invasion. BRD4 inhibition is known to suppress the expression of multiple oncogenes in both hematological and solid malignancies. Together, AXL and BRD4 are among the highest potential oncogenic targets under active research by the pharmaceutical industry due to their association with several indications, many of which have high unmet medical needs. However, the therapeutic small molecule specific for BRD4 or AXL has not yet been approved by the Food and Drug Administration. Thus, new approaches are clearly needed for small molecule drug development for AXL and BRD4.

The discovery of drug models for multiple new chemotypes with activity against these high-value targets represents a major advance. Rapid discovery of these treatment candidates is enabled by the company’s Galileo™ Drug Discovery Platform. Bastian Bergmann, PhD, vice president of engineering at Model Medicines, noted that “the company’s AI drug discovery platform has now established a strong track record for better, faster, cheaper, and reproducible drug discovery—identifying drugs with novel activity against many of the targets that have already been verified. their validity in indications ranging from oncology to infectious disease to bowel dyskinesia.In the case of tumors, the historical lack of success in drug development against AXL and BRD4 necessitated a new approach.Within weeks, we were able to leverage our platform to move from target selection to in silico Discovery in the laboratory Multiple hit validation with drug-like properties – demonstrating the platform’s ability to achieve new discoveries in a timeframe and cost previously unimaginable in the industry.”

“Model Medicines was launched with the goal of building a technology-driven pharmaceutical company that will transform pharmaceutical economic models for drug development and best-in-class therapies discovery against the most difficult drug targets and the most difficult to treat diseases. Rapid drug discovery Multiple compounds with novel activity against two high-value targets in the sciences Oncology, combined with the previously reported potential of MDL-001 to improve treatment options across a wide range of infectious diseases, demonstrates the platform and team’s ability to work across broad areas of human biology and pathology.We look forward to combining our unique innovative approach To numb critical tumor targets with the world’s best translated scientists and drug developers in search of more effective cancer treatments.” Commented by Daniel J. Haders II, Ph.D., co-founder and CEO of Exemplary Pharmaceuticals.

About the typical medicines

Model Medicines is a pharmaceutical company that is transforming the drug discovery and development industry by accelerating the creation of life-changing drugs using artificial intelligence and machine learning. Prototype drugs began in 2019 to fulfill the promise of AI drug discovery. With over 90+ origins for over 10 targets, we’re delivering on the promise of drug discovery with AI. The company has developed a powerful suite of patent-pending therapies to treat tumors, infectious diseases, stomach disorders, neurological disorders and weight disorders. The company is headquartered in La Jolla, California. www.modelmedicines.com

Cision View original content for multimedia download:https://www.prnewswire.com/news-releases/model-medicines-announce-launch-of-oncology-programs-with-multiple-ai-discovered-compounds-demonstrating-drug-like-activity-for-two- High-value-hard-drug-carcinogenic-and-gene targets-301640018.html

Source Model Medicines

Leave a Comment